Journal of Pharmacy And Bioallied Sciences
Journal of Pharmacy And Bioallied Sciences Login  | Users Online: 4290  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 
    Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission




 
 Table of Contents  
REVIEW ARTICLE
Year : 2021  |  Volume : 13  |  Issue : 6  |  Page : 921-926  

COVID-2019–2020–2021: Systematic review and meta-analysis


1 Department of Oral and Maxillofacial Surgery, C.K.S. Teja Institute of Dental Sciences, Tirupathi, Andhra Pradesh, India
2 MBBS, Duty Doctor (DMO), Apollo Hospital, Visakhapatnam, Andhra Pradesh, India
3 Kiran's Poly Clinic, Visakhapatnam, Andhra Pradesh, India
4 Department of Prosthodontics, Educare Institute of Dental Sciences, Malappuram, Kerala, India
5 Consultant Oral and Maxillofacial Surgeon, Amritsar, Punjab, India
6 Consultant Dental Surgeon, 3609 Gracie Ct, Cakersfield, CA, USA
7 MPH Student, Parul University, Vadodara, Gujrat, India

Date of Submission06-May-2021
Date of Decision15-May-2021
Date of Acceptance28-May-2021
Date of Web Publication10-Nov-2021

Correspondence Address:
Heena Tiwari
Parul University, Limda, Waghodia, Vadodara, Gujrat
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jpbs.jpbs_371_21

Rights and Permissions
   Abstract 


Introduction: The world has faced the pandemic of COVID-19 in March 2020 and still it continues to affect in 2021. There is a great variation about the course of the disease and its features. Hence, in the present systemic review, we intend to determine the pooled estimations in the clinical features and prognosis along with the subgroups based on the severity of the disease in various regions of the world. Materials and Methods: Online data were collected from the search engines of EBSCO, PubMed, Google Scholar, and Scopus. The searched terms were COVID 19, CORONA, SARS-CoV-2, clinical features, Wuhan, etc. The study articles were collected that from January 2020 to February 2021. Based on the PRISMA guidelines, a meta-analysis was performed. Results: A total of 5067 articles were selected, of which 176 were finalized for the study. There were a total of 11 countries that were included, with a total of 2½ lakh participants. Mean age was 47.5 years. Around 22.5% had comorbidities. The mortality was 5.5%. We observed a strong association between the medical condition of the patient and the severity of the infection. In severe cases, the most common symptoms were respiratory and gastrointestinal. The mortality was registered in those with pneumonia and end-organ failure. Conclusion: It can be concluded from this meta-analysis that in a fourth of the positive patients, the disease was severe. In nearly 6% of the COVID-19 patients, mortality was seen. Patients with comorbidities and the severe form of the disease should be closely monitored.

Keywords: Clinical features, COVID-19, meta-analysis, outcomes, systemic review


How to cite this article:
Reddy S G, Mantena M, Garlapati SK, Manohar B P, Singh H, Bajwa KS, Tiwari H. COVID-2019–2020–2021: Systematic review and meta-analysis. J Pharm Bioall Sci 2021;13, Suppl S2:921-6

How to cite this URL:
Reddy S G, Mantena M, Garlapati SK, Manohar B P, Singh H, Bajwa KS, Tiwari H. COVID-2019–2020–2021: Systematic review and meta-analysis. J Pharm Bioall Sci [serial online] 2021 [cited 2022 Dec 7];13, Suppl S2:921-6. Available from: https://www.jpbsonline.org/text.asp?2021/13/6/921/330110




   Introduction Top


The world went into a state of standstill after the declaration of the pandemic COVID-19.[1] There has been no specific therapy and treatment for the COVID-19 disease. Only recently, the vaccine has been given in some countries.[2] However, till date, there has been no specific data on the clinical course and the prognosis of the disease.[3],[4],[5],[6],[7],[8] In all the available studies, there were only reports of the cases observed that were admitted into the hospital or in the centers of the specific region care centers.[1],[2],[3],[4],[5],[6],[7],[8],[9]

It is clear from the present studies that there is a great variation in the sociodemographic, clinical course, and the prognosis.[9],[10] A thorough understanding of these features is a necessity for proper treatment planning and establishing a strategy for facing future pandemics. Hence, in the present systemic review, we evaluate and compare the sociodemographic, clinical course, and the prognosis across regions.


   Materials and Methods Top


We conducted the search for the data from online sources such as “EMBASE,” “PubMed,” “Scopus,” and other sources. The study was conducted by two reviewers independently. The PRISMA guidelines were followed.[11] The articles were collected from January 2020 to February 2021. The search words are COVID, COVID19, SARS, CoV2, and PANDEMIC. The animal studies, population data, epidemiology, reviews were excluded. The heterogeneity of the analysis was studied using Cochran Q-statistic and I2 statistic with P < 0.05 for Q-statistic, I2 ≥50% as significant. Total participants, sociodemographic, study type, clinical features, and comorbidities were noted for all the studies. Based on the WHO criteria, meta-regression was performed for the factors that may impact the severity.[12],[13],[14] A statistical analysis was done keeping P < 0.05.


   Results Top


In the present study, 5067 articles were selected. One hundred and seventy-six studies were finalized after the deletion of the duplicates, preprints, and special categories like pregnant and pediatric cases. Studies from ten countries were included. The flowchart of the selection of articles is given in [Figure 1]. The clinical characteristics and other features are shown in [Table 1]. The mean age noted is 47.5 years. Almost equal distribution of gender was seen. Polymerase chain reaction was done for the diagnosis of the COVID-19 in almost all the cases, along with computed tomography scan and antigen tests. The incubation period was between 5 and 7 days. No significant difference was seen between the studies for the incubation period. Majority in the initial studies reported traveling history that may be a mode of transmission. There was a significant difference between the hospitalizations between the nations (P = 0.002). The fever was common in all studies; however, there seldom were reports of cold. Shortness of breath was reported in severe cases in half the patients. Gastrointestinal disturbance was seen in majority of the studies with the diarrhea as common complaint. Other significant symptoms were pain in abdomen. Chills, dizziness common in severe cases.
Figure 1: Flowchart describing the selection of the articles

Click here to view
Table 1: Sociodemographic and clinical features among the studies

Click here to view


The pooled data show ~11% admissions in intensive care unit (ICU) and nearly 6.8% requiring ventilators. Approximately one-fourth of the patients had severe disease [Figure 2]a and [Figure 2]b. Among those with the severe disease, the aged male people were significantly more (P < 0.0001). A significant association was seen between diabetes, hypertension, malignancy, renal diseases, organ failure, and the severity [Figure 2]c. The mortality was ~ 6%, and there was a difference significantly seen among the countries, P < 0.0001 [Figure 2]d.
Figure 2: (a) Distribution of Admitted to intensive care unit in various countries. (b) Distribution of requirement of ventilators among countries. (c) Distribution of severity among countries. (d) Distribution of mortality among countries

Click here to view


When laboratory investigations were assessed, the serum creatinine, lactate dehydrogenase, C-reactive protein, white blood cell, neutrophil count, alanine aminotransferase, aspartate aminotransferase, and procalcitonin were consistently high in the severe than moderate patients. However, the lymphocytes were lower. Similarly, they were higher in mortality cases also.

Meta-regression depicted a significant association between disease severity and various factors. These factors are diabetes, abdominal pain, immunosuppression, and malignancy [Table 2]. In those with, mortality was reported a significant presence of comorbidities and higher age along with ARDS, renal failure, cardiomyopathies, and lung infections [Table 3].
Table 2: Association of the COVID-19 and severity

Click here to view
Table 3: Association of the COVID-19 and mortality

Click here to view



   Discussion Top


In the present meta-analysis a total of 176 articles were taken around the world that includes 10 countries. Maximum data is from the West. A total of nearly 2.5 lakh patients were included. It was observed that middle-aged men were at higher risk of contracting the disease. This distribution was similar in all the countries. The disease severity was seen in 22.5% of the cases, and similarly, mortality was seen in nearly 6% of the cases. The maximum severity and mortality of the patients was seen in Wuhan followed by European countries. In the severe cases also, men were slightly greater than women and of middle age.

Within these infected patients, the comorbidities such as diabetes, hypertension, malignancy, renal diseases, and organ failure were seen more as the severity increased. Hence, these patients may be identified at the earliest diagnosis, and proper attention be given to them.

The pooled average time of onset to hospitalization was 6 days averaging between 5 and 7 days. A greater number of ventilator support and ICU admissions were seen in China than other regions. This is obvious with the strain first spreading in China. This also suggests us that the early identification will prevent the loss of life and prevent the burden on the health-care workers.

We observed that though an uncommon symptom, the pain in the abdomen was associated with the severe disease, and it was significant. Not only that these patients are to be watched cautiously also in the patients with lower counts of lymphocytes and levels of albumin have been associated with quick progress to severity. It can be proposed from our study that in the poor nutritional status, the disease severity and mortality were greater as seen in the levels of albumin. Furthermore, this view is supported by the greater number of patients with severity of disease in those with lower nutritional diet like in old-age homes where greater mortality was reported.[15] Hence in those patients who have lower immunity and nutrition they must be closely monitored for the progression of the disease. The health systems have to mobilize in these areas where facilities may be low.[16] Additional research has to be done in this area to know the exact association between these variables and the outcome.

There were few limitations in our study. We were unable to classify the age groups as there were data with no specific age group classification. It is expected to have unreported cases that are higher than registered. Furthermore, the estimate that we have presented in the study is from the clinical setup and hence might be overestimated.[17] In a recent study, the mortality was as high as 22%.[18] This was reported in the USA. Another limitation in the present review and meta-analysis was that higher than normal routine clinical presentations may have been reported as we considered the clinical reports as well. Hence, there might have been a bias toward an increased report of the mortality. We took care to include the studies with >50 patients. The various systems and protocol of the reporting of the death in case of the COVID-19 may have led to the variation among the nations. There may be reported death that may have been considered as the direct cause of the COVID-19. The deaths happening in these patients may have been missed. This could lead to a bias in the actual number of mortalities and risks associated with it.

Accordingly, a general definition has to be established to define COVID deaths. The general criteria to conclude as a death due to COVID have to be given. This is essential for the nations to establish management strategies in handling the pandemic for the health department. This may be different for the different countries. Some of the studies considered in our analysis were hospital based that may have reported critical and severe cases that may lead to increased mortality rates in their studies. This may not be generalized to the population as many are asymptomatic or mild.

Ultimately, with the rapid spread of the pandemic in various countries, there have been new studies with respect to the probability of the second and third waves. A much detailed analysis with the latest data and the consideration of all the types of cases has to be collected for a better understanding and strategic planning.


   Conclusion Top


It can be concluded from this meta-analysis that in a fourth of the positive patients, the disease was severe. In nearly 6% of the COVID-19 patients, mortality was seen. Patients with comorbidities and the severe form of the disease should be closely monitored. These data from this study may be used to educate health workers and policymakers to better face any pandemic while still facing the current one. This may also help in identification of the risk groups.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020;91:157-60.  Back to cited text no. 1
    
2.
Young BE, Ong SW, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020;323:1488-94.  Back to cited text no. 2
    
3.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708-20.  Back to cited text no. 3
    
4.
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475-81.  Back to cited text no. 4
    
5.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061-9.  Back to cited text no. 5
    
6.
Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington State. JAMA 2020;323:1612-4.  Back to cited text no. 6
    
7.
Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology 2020;295:202-7.  Back to cited text no. 7
    
8.
Wang Y, Liu Y, Liu L, Wang X, Luo N, Ling L. Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China. J Infect Dis 2020;221:1770-4.  Back to cited text no. 8
    
9.
Mizumoto K, Chowell G. Estimating risk for death from coronavirus disease, China, January-February 2020. Emerg Infect Dis 2020;26:1251-6.  Back to cited text no. 9
    
10.
Baloch S, Baloch MA, Zheng T, Pei X. The coronavirus disease 2019 (COVID-19) pandemic. Tohoku J Exp Med 2020;250:271-8.  Back to cited text no. 10
    
11.
Wang Y, Liu Y, Liu L, Wang X, Luo N, Li L. Clinical Outcomes in 55 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission in Shenzhen, China. J Infect Dis 2020;221:1770-4.  Back to cited text no. 11
    
12.
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019;200:e45-67.  Back to cited text no. 12
    
13.
World Health Organization. 2020. Clinical Management of Severe Acute Respiratory Infection when COVID-19 Disease is Suspected: Interim Guidance; World Health Organization. Available from: https://apps.who.int/iris/ handle/10665/331446. License: CC BY-NC-SA 3.0 IGO. [Last accessed on 2020 Mar 13].  Back to cited text no. 13
    
14.
Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to Meta-Analysis, p. 190. Available from: https://www.meta-analysis.com/downloads/Meta-analysis/Metaregression.pdf. [Last accessed on 2020 Jul 08].  Back to cited text no. 14
    
15.
Barnett ML, Grabowski DC. Nursing Homes Are Ground Zero for COVID-19 Pandemic. JAMA Health Forum; 2020. Available from: https://jamanetwork.com/Channels/health-forum/fullarticle/2763666.  Back to cited text no. 15
    
16.
World Population Prospects 2019. New York: United Nations. Available from: https://population.un.org/wpp/.  Back to cited text no. 16
    
17.
Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 infection in children. N Engl J Med 2020;382:1663-5.  Back to cited text no. 17
    
18.
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 2020;323:2052-9.  Back to cited text no. 18
    


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1], [Table 2], [Table 3]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
    Materials and Me...
   Results
   Discussion
   Conclusion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed620    
    Printed14    
    Emailed0    
    PDF Downloaded80    
    Comments [Add]    

Recommend this journal